StockTipsArenaBeta

BUY Marksans Pharma Limited — Aastha Jain, Hem Securities

BUYMarksans Pharma Limited

byAastha Jain, Hem SecuritiesHorizon: NA (inferred Swing (≤2wk))13 Aug 2026via Zee Business (Live)

Entry₹313Inferred
Target₹330
Total upside +5.43% (call closed)
Stop loss₹285-8.95% risk
Exit₹33014 Aug 2026, 2:00 pm
Target hit+5.43%0.00%upside left
Follow Aastha Jain for new calls(34% target hit, 58 closed calls)Get alertsWatch MARKSANS for new buy/sell callsGet alertsSee 263 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Aug 2026
6 supporting1 neutral0 opposing
Supports the BUY call (6)

Earnings Central: Tata Motors, HAL, Grasim and Lenskart lead a mixed Wednesday

NewsCnbc-Tv18·12 Aug · yesterday

(opens in new tab)

Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore

NewsEt-Markets·12 Aug · yesterday

(opens in new tab)

Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands

NewsCnbc-Tv18·12 Aug · 2d ago

(opens in new tab)

Marksans Pharma reported record Q1FY27 results with all-time high profitability and cash balance crossing ₹1,000 crore. EBITDA rose 113% YoY to ₹213 crore, and PAT grew 174% YoY to ₹159 crore. UK & Eu

NSE · Press Release·12 Aug · 2d ago

(opens in new tab)

Marksans Pharma reported record Q1FY27 financial results with all-time high profitability and cash balance exceeding ₹1,000 crore. EBITDA rose 113% YoY to ₹213 crore, and PAT grew 174% YoY to ₹159 cro

BSE · Company Update·12 Aug · 2d ago

(opens in new tab)
Neutral / worth noting (1)

Marksans Pharma Ltd announced that its Board of Directors approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026, during a meeting held on August 12

BSE · Board Meeting·12 Aug · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.